TriangleCemiplimab Plus Gemcitabine (NCT06790602)
Cemiplimab Plus Gemcitabine trial for Pancreatic Ductal Adenocarcinoma (mPDAC) (NCT06790602). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic pancreatic ductal adenocarcinoma carrying a SWI/SNF alteration. One prior treatment line is required; the study targets patients whose FOLFIRINOX or gemcitabine/nab-paclitaxel failed or was intolerable. Prior checkpoint immunotherapy excludes entry.
The idea: cemiplimab blocks the PD1 immune brake; gemcitabine disrupts DNA production. Cemiplimab infusions repeat every two weeks. Gemcitabine is infused on days one, eight, and fifteen of each twenty-eight-day cycle. Researchers assess survival outcomes.
This phase 2 study plans 43 patients. Gregory Botta leads at UC San Diego, La Jolla, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.